Merus NV (FRA:2GH)
€ 48.4 -0.4 (-0.82%) Market Cap: 3.34 Bil Enterprise Value: 3.04 Bil PE Ratio: 0 PB Ratio: 8.88 GF Score: 57/100

Merus NV at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript

Feb 10, 2022 / 03:30PM GMT
Release Date Price: €22.6 (+4.63%)
Charles Zhu
Guggenheim Partners - Analyst

Hello, everyone, and welcome back. I am Charles Zhu, one of the senior biotech analysts here at Guggenheim Securities. Our next fireside chat will be with Merus, a clinical-stage oncology biotech with a bispecific antibody platform. Joining us is CEO, Bill Lundberg.

Bill, I want to say thank you very much for your time this morning. We really appreciate it, and we are really happy to have you on board. Perhaps, before we jump into Q&A, would you be able to provide us just a two- to three-minute overview of Merus's pipeline platform as well as some of your particular assets?

Bill Lundberg
Merus N.V. - President, CEO, Principal Financial Officer, & Executive Director

Yeah. First, let me thank you, Charles, for your support and the opportunity to speak and share the fireside chat with you today. And thanks to the support from the entire Guggenheim team. It's really helpful.

Merus is a bispecific or multispecific antibody company focused on therapies for cancer. And our whole platform is based

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot